


Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: -----




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas




Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 11551




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: .




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL\_programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles; Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 1




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




⊘: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: \_\_\_\_\_



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas




Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/Figures/Figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure 15.4.2.9.sas



Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/Figures/Figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 2012/1007




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas






Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL\_programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




⊘: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2.

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL\_programs/Figures/Figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: [REDACTED]




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 0




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/Figures/Figure 15.4.2.9.sas




Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas






Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 15.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Levothyroxine  
EMR 200125-001


Bioequiv: EMR200125-001 Page 847 of 1628 ulation vs. old formulation

Merck Serono  
EMR 200125-001

Page 90 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: [REDACTED]



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/figures/figure  
 15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas




Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



⊗: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas




Merck Serono

Confidential

EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new Formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas






Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: ?




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




⊖: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Levothyroxine  
EMR 200125-001


Bioequiv: EMR200125-001 Page 869 of 1628 ulation vs. old formulation

Merck Serono  
EMR 200125-001

Page 112 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: \_\_\_\_\_




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas




Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (For Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: J




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: ...




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas






Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 2




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: :




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/Figures/Figure  
15.4.2.9.sas






Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas




Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 7



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

